anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Eligible patients not accepting early minimally invasive surgery are classified as the conventional treatment group. Conventional treatment includes medical treatment and conventional craniotomy. According to the intention-to-treat principle, patients treated by minimally invasive surgery beyond the 24 hours interval after ICH onset are also classified as conventional treatment group.
The invention relates to a traditional Chinese medicine with a skin whitening function. The traditional Chinese medicine is composed of the following medicinal materials in parts by weight: 20 to 40 parts of bee pollen, 20 to 40 parts of pearl powder, 20 to 30 parts of dahurian angelica root, 20 to 40 parts of bletilla striata, 25 to 40 parts of white muscardine silkworm, 20 to 40 parts of rhizoma kaempferiae, 10 to 20 parts of towel gourd, 20 to 40 parts of rhizoma nardostachyos, 15 to 30 parts of safflower, 15 to 30 parts of seed of Job's tears, 20 to 40 parts of ampelopsis japonica, and 20 to 40 parts of almond. Because the components of the traditional Chinese medicine are all chosen from traditional Chinese medicines, the traditional Chinese medicine will not do harms to human skins. Rhizoma nardostachyos, rhizoma kaempferiae, and dahurian angelica root all have strong functions of penetrating and promoting human skin blood circulation, and can promote the skin cells' metabolism. Bee pollen, pearl powder, bletilla striata, and white muscardine silkworm all have the skin whitening function. By adopting the traditional Chinese medicine mentioned above, the drug effect can be enabled to effectively penetrate the human skin, and achieves a good skin whitening effect.
Limiting access to a firearms during suicidal crisis can save lives. This study will test a patient decision aid about safe firearm storage during crisis. The investigators will enroll 60 adult emergency department patients being evaluated for suicidal risk and have at least one firearm at home. If available, the investigators will also enroll a family member or friend. Participants will randomly receive one of two things: the decision aid or general suicide prevention information. A week later, the investigators will call participants to see how both groups choose to store their firearms. This trial tests the acceptability of the decision aid, effects on decision making, effect on home storage, effect on suicide outcomes, and feasibility of a larger trial. The investigators hypothesize that participants with higher quality decisions after the decision aid will be more likely to change their firearm storage to reduce access during the time of crisis; should the pilot demonstrate feasibility, in a subsequent larger trial this hypothesis would be tested directly.
The invention relates to a complex of at least one lipophilic acid and mitoxantrone (1,4-dihydroxy(5,8-bis{{2-{2-[(hydroxyethyl)amino]-ethyl}amino}}-9,1-a nthracenedione dihydrochloride (NSC-279836)) and/or bisantrene (9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazole-2-yl)hydrazone dihydrochloride (NSC 337766)), to a composition of a biologically tolerable organic excipient and the previously mentioned complex, and to a remedy containing the complex or the composition. Mitoxantrone has been hitherto administered in the form of an aqueous solution. Administration in the doses necessary for cytostasis, however, causes serious side effects. The cytostatics mitoxantrone and/or bisantrene should therefore be made available in a form which leads to an increased absorption in the intracellular space and thus to an increased activity of the medicaments. A complex of at least one lipophilic acid and mitoxantrone and/or bisantrene as well as a composition of a biological tolerable organic excipient and the previously mentioned complex as well as a remedy which contains the complex and/or the composition are made available. The complex of a lipophilic acid and one of the cytostatics has a substantially increased cytotoxic action in comparison to the free preparation and therefore enables the doses to be administered to be drastically reduced. The complex according to the invention can be employed for the therapy of carcinomas, for example of breast cancer, acute leukaemia and lymphomas.
PURPOSE: To obtain a toothpaste composition excellent in the dispersion stability of an abrasive even in a long time storing, almost free from roping and having excellent usability by compounding the abrasive in an aqueous medium and further adding a specific polysaccharide into the mixture. CONSTITUTION: Into an aqueous medium, 5-50wt.% of an abrasive is compounded, and subsequently, gelan gum is added into the obtained composition. The gelan gum is preferably added in an amount of 0.05-5wt.% based on the total amount of the composition. Further preferably, the composition is compounded with 5-40wt.% of the abrasive, and it is a liquid having a viscosity of 20-180 poise and a yield value of 1-60 pascal each at 25 deg.C. The abrasive is e.g. a precipitated silica, zirconosilicate and calcium phosphate.
A randomized study is planned over 5 years to evaluate the effectiveness of the Therapeutic Workplace in promoting naltrexone adherence in opiate-dependent adults. An extended-release depot formulation of naltrexone will be used. Participants will be offered an inpatient opioid detoxification and naltrexone induction. Participants who complete the oral naltrexone induction will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Patients in the "Work Plus Naltrexone Contingency" condition will earn access to working and earning salary by taking depot naltrexone once per month. "Work Plus Naltrexone Prescription" participants will be encouraged to take depot naltrexone monthly, but access to working and earning salary will not be contingent on doing so.
Cytokine mediated sustained inflammation increases the risk to develop different complex chronic inflammatory diseases, but the implicated mechanisms remain unclear. Increasing evidence shows that long noncoding RNAs (lncRNAs) play key roles in the pathogenesis of inflammatory disorders, while inflammation associated variants are described to affect their function or essential RNA modifications as N6-methyladenosine (m6A) methylation, increasing predisposition to inflammatory diseases. Here, the functional implication of the intestinal inflammation associated lncRNA LOC339803 in the production of cytokines by intestinal epithelial cells is described. Allele-specific m6A methylation is found to affect YTHDC1 mediated protein binding affinity. LOC339803-YTHDC1 interaction dictates chromatin localization of LOC339803 ultimately inducing the expression of NFκB mediated proinflammatory cytokines and contributing to the development of intestinal inflammation. These findings are confirmed using human intestinal biopsy samples from different intestinal inflammatory conditions and controls. Additionally, it is demonstrated that LOC339803 targeting can be a useful strategy for the amelioration of intestinal inflammation in vitro and ex vivo. Overall, the results support the importance of the methylated LOC339803 lncRNA as a mediator of intestinal inflammation, explaining genetic susceptibility and presenting this lncRNA as a potential novel therapeutic target for the treatment of inflammatory intestinal disorders.
Caution should be exercised in the handling and preparation of solutions of Ganciclovir Injection. Solutions of Ganciclovir Injection are alkaline (pH 11). Avoid direct contact of the skin or mucous membranes with Ganciclovir Injection solution. If such contact occurs, wash thoroughly with soap and water; rinse eyes thoroughly with plain water. Wearing disposable gloves is recommended.

Because ganciclovir shares some of the properties of antitumor agents (i.e., carcinogenicity and mutagenicity), consideration should be given to handling and disposal according to guidelines issued for antineoplastic drugs 1 Discard any unused portion of the reconstituted solution [see How Supplied/Storage and Handling (16)].
<P>PROBLEM TO BE SOLVED: To provide a skin cosmetic which is not sticky, has excellent compatibility with the skin, gives an excellent sense of use, and imparts healthy gloss and flexible tension to the skin.  <P>SOLUTION: This skin cosmetic is characterized by containing a highly polymerized silicone oil having a polymerization degree of ≥800 and/or a viscosity of ≥10,000 centistokes at 25°C. The skin cosmetic further contains hydrogenated lecithin. The skin cosmetic furthermore contains phenyl trimethicone (methylphenylpolysiloxane) and trimethylglycine. In particular, the skin cosmetic contains a highly polymerized chain dimethylpolysiloxane having a polymerization degree of 2,300 and/or a viscosity of 1,000,000 centistokes at 25°C.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A novel compound which is useful as a therapeutic or preventive agent for diseases attributable to gastric hydrochloric acid. It has excellent gastric hydrochloric acid secretion inhibitory activity and is richer in the retention of gastric hydrochloric acid secretion inhibitory activity. It can keep the gastric pH high for long. It is safer and has moderate physicochemical stability. It is a compound represented by the general formula (1) (wherein R and R are the same or different and each represents hydrogen or C alkyl; R represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy, (2,2-dimethyl-1,3-dioxan-5-yl)methoxy, etc.; R, R, R, and R each represents hydrogen, halogeno, C alkyl, C haloalkyl, C alkoxy, C haloalkoxy, etc.; and W represents a single bond, methylene, or ethylene), a salt thereof, or a solvate of either.
The link between cellular exposure to fatty acid species and toxicity phenotypes remains poorly understood. However, structural characterization and functional profiling of human plasma free fatty acids (FFAs) analysis has revealed that FFAs are located either in the toxic cluster or in the cluster that is transcriptionally responsive to lipotoxic stress and creates genetic risk factors. Genome-wide short hairpin RNA screen has identified more than 350 genes modulating lipotoxicity. Hypertrophic adipocytes in obese adipose are both unable to expand further to store excess lipids in the diet and are resistant to the antilipolytic action of insulin. In addition to lipolysis, the inability of packaging the excess lipids into lipid droplets causes circulating fatty acids to reach toxic levels in non-adipose tissues. Deleterious effects of accumulated lipid in non-adipose tissues are known as lipotoxicity. Although triglycerides serve a storage function for long-chain non-esterified fatty acid and their products such as ceramide and diacylglycerols (DAGs), overloading of palmitic acid fraction of saturated fatty acids (SFAs) raises ceramide levels. The excess DAG and ceramide load create harmful effects on multiple organs and systems, inducing chronic inflammation in obesity. Thus, lipotoxic inflammation results in β cells death and pancreatic islets dysfunction. Endoplasmic reticulum stress stimuli induce lipolysis by activating cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) and extracellular signal-regulated kinase (Erk) 1/2 signaling in adipocytes. However, palmitic acid-induced endoplasmic reticulum stress-c-Jun N-terminal kinase (JNK)-autophagy axis in hypertrophic adipocytes is a pro-survival mechanism against endoplasmic reticulum stress and cell death induced by SFAs. Endoplasmic reticulum-localized acyl-coenzyme A (CoA): glycerol-3-phosphate acyltransferase (GPAT) enzymes are mediators of lipotoxicity, and inhibiting these enzymes has therapeutic potential for lipotoxicity. Lipotoxicity increases the number of autophagosomes, which engulf palmitic acid, and thus suppress the autophagic turnover. Fatty acid desaturation promotes palmitate detoxification and storages into triglycerides. As therapeutic targets of glucolipotoxicity, in addition to caloric restriction and exercise, there are four different pharmacological approaches, which consist of metformin, glucagon-like peptide 1 (GLP-1) receptor agonists, peroxisome proliferator-activated receptor-gamma (PPARγ) ligands thiazolidinediones, and chaperones are still used in clinical practice. Furthermore, induction of the brown fat-like phenotype with the mixture of eicosapentanoic acid and docosahexaenoic acid appears as a potential therapeutic application for treatment of lipotoxicity.
Belatacept: infusion on Days 1, 15, 29, 43, 57 then every 28 days. All patients received a background maintenance immunosuppressive regimen of mycophenolate mofetil or mycophenolic acid, with adjunctive corticosteroids, according to their immunosuppressive regimen at the time of enrollment.
BACKGROUND: Metastatic lesions to the salivary gland are rare and mostly affect the parotids. Metastases represent 8% of all malignant lesions of the parotid gland. Around 80% originate from squamous cell carcinomas (SCC) of the head and neck region. Fine needle aspiration (FNA) plays a crucial role in distinguishing primary salivary gland lesions from metastases. Herein we describe our series of metastases to the parotid glands.
MATERIALS AND METHODS: We analysed 630 parotid gland FNAs over a decade including conventional and liquid-based cytology specimens. Ancillary techniques such as immunocytochemistry (ICC) were conducted on cell blocks.
RESULTS: Eighty (12.4%) cases were malignant lesions, of which 53 (63.75%) were metastases including 24% melanoma, 22.6% SCC, 19% renal carcinomas, 7.5% breast carcinomas, 11.3% lung, 9% intestinal and 1.8% testicular, malignant solitary fibrous tumour and Merkel cell carcinoma. The 53 cases, classified according to the Milan system for salivary cytopathology, belonged to 5 Suspicious for malignancy (SFM) and 48 malignant (M) categories. Forty had a known history of primary malignancy (75.4%), while 13 were suspicious to be a metastatic localisation (24.5%), distributed as 5SFM (2SCC and 3Melanoma) and 8 M. A combination of clinical history, cytomorphology and ICC identified 100% of them.
CONCLUSIONS: Fine needle aspiration plays a central role in the diagnostic workup of patients with metastatic lesions to their parotid glands, thereby defining the correct management. Diagnostic accuracy may be enhanced by applying ICC. Although melanoma and SCC are the most common histological types, several other malignancies may also metastasize to the parotid glands and should be kept into consideration.
The invention discloses a traditional Chinese medicine preparation for treating breast cancer and a preparation method thereof. The traditional Chinese medicine preparation is prepared from the following raw materials by weight: 5 to 30 parts of baikal skullcap root, 5 to 30 parts of red paeonia, 5 to 30 parts of tree peony bark, 10 to 50 parts of cortex albiziae, 5 to 30 parts of fried gardenia, 10 to 50 parts of trumpet creeper, 5 to 30 parts of plum flower bud, 10 to 50 parts of Glehnia Root, 10 to 50 parts of ruddle, 10 to 50 parts of fried Rhizoma Atractylodis Macrocephalae, 5 to 30 fried parts of radix bupleuri, 5 to 30 parts of roasted pangolin, 10 to 50 parts of turtle shell, 10 to 50 parts of Viscum album, 10 to 50 parts of windpipe, 10 to 50 parts of fingered citron, 10 to 50 parts of date and 5 to 30 parts of broiled liquorice. The invention has the efficacies of heat and toxic material cleaning, soften hard lump softening and node dispelling, qi tonifying, blood nourishing, heart calming and mind tranquilizing, is used for treating breast cancer which pents up scorchingly hot, losses qi and blood and invaginates pathogenic toxin. The breast cancer has the symptoms that breast lumps enlarge to extend to chests and the upper parts and the lower parts of clavicles, and are even transferred to liver, lung, skeletons and brains. Besides, the breast cancer has the symptoms of palpitation, mental fatigue, hypodynamia, sleeplessness, night sweat, diarrhea, clear abundant urine, dull tongue with whitish and greasy coating, and forceless deep and thready pulse. The traditional Chinese medicine preparation for treating breast cancer has effective curative effect and is safe and nontoxic.
The present invention relates to traditional Chinese medicine for preventing and curing recurrent respiratory tract infection. The present invention is characterized in that the present invention is prepared from 10 to 20g of astragalus root, 6 to 12g of heterophylly falsestarwort root, 6 to 12g of rehmannia root, 12 to 24g of shiitake fungus and 2 to 4g of liquorice. The astragalus root and the heterophylly falsestarwort root in a prescription are sweet in flavor and slightly warm in nature. The astragalus root and the heterophylly falsestarwort root enter the lung and the spleen channel for invigorating qi of the spleen and the lung and are sovereign medicine. Red sage root is bitter in taste, is slightly warm in nature, activates blood circulation, removes blood stasis and is auxiliary medicine. The rehmannia root has two functions: on one hand, the function of removing pathogenic heat from blood is used for assisting the blood circulation activation and blood stasis removal; on the other hand, the rehmannia root is sweet in flavor and cold in nature and can be used for curing the sweet nature and warm nature of other kinds of medicine in the prescription. The shiitake fungus supports the healthy energy, supplements vacuity, strengthens the spleen and promotes appetite, and the shiitake fungus and the rehmannia root are auxiliary medicine. The liquorice moistens the lung, arrests cough and adjusts other kinds of medicine as auxiliary medicine. The medicine in prescription has the function of tonifying the lung and the spleen, benefiting qi and activating blood circulation. By the certification of modern medicine theory and research, the heterophylly falsestarwort root, the rehmannia root, the shiitake fungus and the liquorice can adjust and enhance immunological function, have the action of resisting pathogenic animalcules and have good curing effect for curing asthenia of qi in the lung and the spleen and blood stasis of recurrent respiratory tract infection.
This invention is a method for treating human erectile dysfunction using therapeutic amounts of human growth hormone (GH) administered systemically. Severing the parasympathetic nerves that regulate the erectile function during the course of surgery produces erectile dysfunction. Damage to these nerves by diseases such as diabetes mellitus and alcoholism and during aging may also produce erectile dysfunction. GH stimulates the regeneration of severed parasympathetic nerves that regulate the erectile function restoring potency. GH may act directly or by stimulating the production of insulin-like growth factor-I (IGF-I). The combination of GH plus an IGF (with or without one of the IGF binding proteins) may provide a better response than GH alone.
A therapeutic product delivery device is described which comprises a device body and a cartridge for holding a therapeutic product. An engagement structure is provided for releasably engaging the cartridge with the device body. A fault detector is provided for detecting a fault in the delivery of the therapeutic product from the cartridge. A release trigger is responsive to the detection of a fault to cause the engagement structure to release the cartridge from the device body. In this way, a fault causes the cartridge to be released from the device body, which will prevent any further delivery of the therapeutic product to the patient. This solution is strongly preferable to a solution in which a product delivery mechanism (e.g. a pump) is merely paused or stopped, since when the cartridge separates then no further delivery is possible at all, until the cartridge is reattached (or more probably replaced with a new cartridge in case the fault is with the cartridge).
The attention control condition consists of two unique components in addition to the standard iExposure intervention (1) the intervention rationale will include information about the importance of developing attention control; (2) participants will be given a central region of the screen (non-audience member) to focus on. They will be told that they should look at and focus on the central region for the whole response.
For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who will develope T2DM during the follow-up will be divided into the group"COPD patients with T2DM".
A cosmetic having anti-perspirant properties comprises an aluminium chlorohydrate in which the molecular ratio of aluminium to chloride is 2 : 1 in a vehicle containing an emulsifier, the chlorohydrate being present in 5-20 per cent and preferably 15 per cent by weight of the preparation.  A chlorohydrate of probable formula Al6 (OH)15Cl3 (see Group XXXVI) is specified and may be used in solution or in an emulsion or cream, the pH of a 15 per cent solution being 4.38.  An example is given of a solution in aqueous alcohol containing glyceryl monostearate, which is suitably perfumed.  There are many examples of creams and emulsions.  According to one such, stearic acid, beeswax, mineral oil and glyceryl monostearate are melted together at approximately 80 DEG C, propylene glycol is dissolved in an aqueous solution of sodium lauryl sulphate, the solution so formed heated to approximately 80 DEG C and poured into the previously prepared stearic acid mixture, the whole being heated to 100 DEG C and stirred until set.  An aqueous solution of the aluminium chlorohydrate is incorporated when the mass has cooled to 20 DEG -25 DEG C.  In general such preparations contain a vehicle, humectant emulsifier and the aluminium chlorohydrate.  Specified vehicles, which may comprise 8 to 15 per cent and preferably 11 per cent of the preparation, are one or more of the following:-A higher fatty acid, e.g. stearic and palmitic acid, mineral oil, beeswax, petroleum jelly, spermaceti, ceresin and magnesium or zinc stearate. As emulsifiers, comprising 6 to 15 per cent, preferably 10 per cent, of the preparation there are one or more of the following partial fatty acid esters of polyhydric alcohols, e.g. the lauric, myristic, stearic, palmitic and oleic acid esters of glycerol, the sugar alcohols, e.g. sorbitol, mannitol and dulcitol and inner anhydrides thereof; glyceryl monolaurate, monostearate and monopalmitalc; salts of sulphated higher alcohols, e.g. sodium lauryl sulphate, sodium myristyl sulphate.  Specified humectants are polyhydric aliphatic compounds such as ethylene, propylene and butylene glycols and their lower polymers; polyhydric alcohols such as glycerol, erythritol, sorbitol, mannitol and dulcitol which may be present in the proportion of 3 to 10 per cent, preferably 5 per cent.